The authors were interested in the immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when given together with a quadrivalent seasonal inactivated influenza vaccine (IIV4). They performed a phase 3, open-label, randomised clinical trial in adults aged ≥50 years who were randomised (1:1) to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant System) and IIV4 at day 0 followed by a second HZ/su dose at month 2 (coadministration group), or IIV4 at month 0 and HZ/su at months 2 and 4 (control group). 413 participants were vaccinated in the coadministration group and 415 in the control group. The authors found that the HZ/su vaccine response rate in the coadministration group was 95.8% and the anti-glycoprotein E GMC[Control/Coadmin] ratio was 1.08 (95%CI 0.97-1.20). Therefore noninferiority of HZ/su and IIV4 antibody responses compared with controls is demonstrated. There was no interference in the immune responses to either vaccine when the vaccine was coadministered.
Read more here